AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36871215 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliminating copayments for high-value preventive medications (waived 30% copayment on 15 medication classes)
Number of subjects: 4761
Study 36871215 — intervention group
Group type: COMPARATOR
Intervention: Usual copayment (30% copayment on medications)
Number of subjects: 4761
Study 36871230 — intervention group
Group type: EXPERIMENTAL
Intervention: 3- to 6-month DAPT
Number of subjects: 2013
Study 36871230 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 2013
Study 36871246 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuhan rivaroxaban tablet
Number of subjects: 34
Study 36871246 — intervention group
Group type: COMPARATOR
Intervention: Xarelto tablet
Number of subjects: 34
Study 36871285 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial rate responsive pacing
Number of subjects: 29
Study 36871285 — intervention group
Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 29
Study 36871310 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated healthcare and vocational rehabilitation intervention (INT)
Number of subjects: 631
Study 36871310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental healthcare intervention (MHC)
Number of subjects: 631
Study 36871310 — intervention group
Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 631
Study 36871310 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC
Number of subjects: 631
Study 36871310 — intervention group
Group type: EXPERIMENTAL
Intervention: INT
Number of subjects: 631
Study 36871310 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (INT, MHC)
Number of subjects: 631
Study 36871424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with nab-paclitaxel (nP) and epirubicin/cyclophosphamide
Number of subjects: 50
Study 36871476 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenlingcao oral liquid (SOL) combined with conventional chemotherapy
Number of subjects: 516
Study 36871476 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy alone
Number of subjects: 516
Study 36871487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab with chemotherapy (2 cycles)
Number of subjects: 719
Study 36871487 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (4 cycles)
Number of subjects: 719
Study 36871573 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-physician community health-care provider-led intensive blood pressure intervention
Number of subjects: 33995
Study 36871573 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33995
Study 36871574 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Number of subjects: 433
Study 36871574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433
Study 36871613 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive cardiopulmonary exercise testing
Number of subjects: 35
Study 36871772 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 <1.3 and/or LSM <8 kp (Class A)
Number of subjects: 2523
Study 36871772 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 1.31‒2.6 and/or LSM 8.1-12.5 kp (Class B)
Number of subjects: 2523
Study 36871772 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 >2.6 and/or LSM >12.5 kp (Class C)
Number of subjects: 2523
Study 36871842 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired spirometry findings (COPD)
Number of subjects: 1561
Study 36871842 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired spirometry findings (COPD GOLD stage ≥ 2)
Number of subjects: 1561
Study 36871842 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired spirometry findings (COPD GOLD stage 1)
Number of subjects: 1561
Study 36871842 — intervention group
Group type: COMPARATOR
Intervention: Normal spirometry findings
Number of subjects: 1561
Study 36871848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI)
Number of subjects: 142
Study 36872017 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 5-MTHF
Number of subjects: 292
Study 36872017 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 292
Study 36872017 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula compliant with EU legislation
Number of subjects: 292
Study 36872017 — intervention group
Group type: COMPARATOR
Intervention: TT genotype carriers
Number of subjects: 292
Study 36872016 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful plant-based diet (hPDI)
Number of subjects: 65574
Study 36872016 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthful plant-based diet (uPDI)
Number of subjects: 65574
Study 36872169 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena cava filters (VCFs) implantation
Number of subjects: 1429
Study 36872181 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily (QD)
Number of subjects: 0
Study 36872181 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD
Number of subjects: 0
Study 36872181 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg QD
Number of subjects: 0
Study 36872186 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA) assessment of hemodynamic and plaque characteristics
Number of subjects: 0
Study 36872186 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive fractional flow reserve (FFR)
Number of subjects: 0
Study 36872186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel- and lesion-level hemodynamic characteristics, and vessel-level plaque quantity, and lesion-level plaque compositional characteristics assessed by CTA
Number of subjects: 0
Study 36872337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus apatinib and chemotherapy
Number of subjects: 30
Study 36872457 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with two cycles of 3-weekly docetaxel 75 mg/m² and concurrent chemoradiotherapy (CCRT)
Number of subjects: 171
Study 36872873 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care therapy
Number of subjects: 8007
Study 36872921 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Number of subjects: 501
Study 36872921 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 501
Study 36873397 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant cholesterol quartile (fourth quartile)
Number of subjects: 2823
Study 36873397 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 2823
Study 36873411 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute increase in coronary sinus (CS) pressure during incomplete balloon occlusion
Number of subjects: 20
Study 36873411 — intervention group
Group type: COMPARATOR
Intervention: Sham (deflated balloon in the right atrium)
Number of subjects: 20
Study 36873421 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous ammonia levels
Number of subjects: 549
Study 36873425 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative COVID-19
Number of subjects: 4928
Study 36873425 — intervention group
Group type: COMPARATOR
Intervention: No preoperative COVID-19
Number of subjects: 4928
Study 36873431 — intervention group
Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 100
Study 36873436 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS over the left PPC for 10 consecutive days
Number of subjects: 20
Study 36873436 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study 36873654 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth nutrition intervention
Number of subjects: 38
Study 36873654 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (education) group
Number of subjects: 38
Study 36873751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiofrequency catheter ablation and LAAC procedures
Number of subjects: 931
Study 36873751 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 931
Study 36873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR) in PCI
Number of subjects: 600
Study 36873760 — intervention group
Group type: COMPARATOR
Intervention: Complete Revascularization (CR) in CABG
Number of subjects: 600
Study 36873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete Revascularization (IR) in PCI
Number of subjects: 600
Study 36873760 — intervention group
Group type: COMPARATOR
Intervention: Incomplete Revascularization (IR) in CABG
Number of subjects: 600
Study 36873770 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy after 1-month DAPT
Number of subjects: 5982
Study 36873770 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT with aspirin and clopidogrel
Number of subjects: 5982
Study 36873828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery and physical exercise
Number of subjects: 140
Study 36873828 — intervention group
Group type: COMPARATOR
Intervention: Only physical exercise
Number of subjects: 140
Study 36873865 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT investigation in patients with COVID-19 pneumonia
Number of subjects: 13
Study 36873865 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT as a diagnostic tool
Number of subjects: 13
Study 36873868 — intervention group
Group type: EXPERIMENTAL
Intervention: ROR1 CAR-T cells
Number of subjects: 0
Study 36873868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies targeting other tumor antigens or inhibitors preventing tumor antigenic escape
Number of subjects: 0
Study 36873949 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drinks and dietary factors
Number of subjects: 0
Study 36873989 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab, dosage and duration not available
Number of subjects: 0
Study 36873994 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylone (200 mg)
Number of subjects: 17
Study 36873994 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 17
Study 36873994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 36874115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus Lenvatinib
Number of subjects: 36
Study 36874269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status (measured as serum levels of 25(OH)D)
Number of subjects: 125
Study 36874269 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 125
Study 36874396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg once weekly
Number of subjects: 255
Study 36874396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 36874582 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 36874582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 0
Study 36875061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural administration of oncolytic vaccinia virus (1.00E+07 to 6.00E+09 PFU)
Number of subjects: 18
Study 36875061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural administration of oncolytic vaccinia virus
Number of subjects: 18
Study 36875114 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive clinical evaluation, exome sequencing, copy number variation analysis, autoantibody surveys, peripheral blood immunophenotyping, salivary cytokine analyses
Number of subjects: 1
Study 36875126 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal antibodies avidity resolution tool (PAART)
Number of subjects: 0
Study 36875126 — intervention group
Group type: EXPERIMENTAL
Intervention: Label-free techniques (surface plasmon resonance and biolayer interferometry)
Number of subjects: 0
Study 36875134 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination in the morning
Number of subjects: 0
Study 36875134 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination in the afternoon
Number of subjects: 0
Study 36875134 — intervention group
Group type: COMPARATOR
Intervention: Comparison of morning vs afternoon BCG vaccination
Number of subjects: 0
Study 36875134 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination (morning and afternoon)
Number of subjects: 0
Study 36875317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX) 0.15 mg/kg or MNTX 8 mg/12 mg based on body weight, administered subcutaneously every other day.
Number of subjects: 364
Study 36875317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 364
Study 36875554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucous Fistula Refeeding (MFR)
Number of subjects: 0
Study 36875554 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36875669 — intervention group
Group type: EXPERIMENTAL
Intervention: SCES on (3 mA) in supine
Number of subjects: 1
Study 36875669 — intervention group
Group type: EXPERIMENTAL
Intervention: SCES on (5 mA) in tilt
Number of subjects: 1
Study 36875669 — intervention group
Group type: EXPERIMENTAL
Intervention: SCES on (3 mA) in supine at assessment two
Number of subjects: 1
Study 36875669 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing amplitude to 2 mA
Number of subjects: 1
Study 36875669 — intervention group
Group type: EXPERIMENTAL
Intervention: SCES on (3 mA) in tilt at assessment two
Number of subjects: 1
Study 36875669 — intervention group
Group type: COMPARATOR
Intervention: SCES off
Number of subjects: 1
Study 36875669 — intervention group
Group type: EXPERIMENTAL
Intervention: SCES on
Number of subjects: 1
Study 36875717 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole and Hydroxychloroquine
Number of subjects: 11
Study 36876292 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care interventions initiated by the study team
Number of subjects: 133
Study 36876350 — intervention group
Group type: COMPARATOR
Intervention: First-line anti-TB drugs (rifampicin, isoniazid, pyrazinamide, ethambutol)
Number of subjects: 43
Study 36876480 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent smokers
Number of subjects: 2874
Study 36876480 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers who quit at 3 months
Number of subjects: 2874
Study 36876480 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 2874
Study 36876480 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 2874
Study 36876480 — intervention group
Group type: COMPARATOR
Intervention: Persistent smokers vs. never smokers
Number of subjects: 2874
Study 36876483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 5258
Study 36876483 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 5258
Study 36876594 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 36876735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639
Study 36876735 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study 36876753 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER)
Number of subjects: 350
Study 36876753 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (control)
Number of subjects: 350
Study 36876756 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair plus medical therapy (device group)
Number of subjects: 614
Study 36876756 — intervention group
Group type: COMPARATOR
Intervention: Maximal doses of guideline-directed medical therapy alone (control group)
Number of subjects: 614
Study 36876740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid (180 mg daily)
Number of subjects: 13970
Study 36876740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13970
Study 36876946 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) targeting arm motor function; 36 sessions of 70 minutes each over 6 weeks, half supervised via videoconference; included functional games, exercise videos, education, and daily assessments.
Number of subjects: 19
Study 36876946 — intervention group
Group type: COMPARATOR
Intervention: Usual care (not detailed in the abstract)
Number of subjects: 19
Study 36876957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 2062
Study 36876957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2062
Study 36877099 — intervention group
Group type: EXPERIMENTAL
Intervention: Taletrectinib
Number of subjects: 0
Study 36877099 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 36877099 — intervention group
Group type: COMPARATOR
Intervention: Entrectinib
Number of subjects: 0
Study 36877098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept (0.3 mg/kg starting dose, 0.7 mg/kg target dose, subcutaneous every 3 weeks)
Number of subjects: 323
Study 36877098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 36877098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 323
Study 36877118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation
Number of subjects: 300
Study 36877132 — intervention group
Group type: EXPERIMENTAL
Intervention: Active placebo
Number of subjects: 1462
Study 36877132 — intervention group
Group type: COMPARATOR
Intervention: Standard placebo
Number of subjects: 1462
Study 36877177 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated, multifaceted intervention
Number of subjects: 1049
Study 36877177 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1049
Study 36877234 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 522
Study 36877259 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionic pancreas (BP)
Number of subjects: 0
Study 36877259 — intervention group
Group type: EXPERIMENTAL
Intervention: Backup insulin regimens generated by the BP
Number of subjects: 0
Study 36877259 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting insulin dose, four-period basal insulin profile, short-acting meal doses, glucose correction factor
Number of subjects: 0
Study 36877480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), delivered weekly for 16 weeks
Number of subjects: 64
Study 36877502 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (coronary angiography and revascularization if feasible; n=84)
Number of subjects: 167
Study 36877502 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (medical treatment with coronary angiography for recurrent ischemia; n=83)
Number of subjects: 167
Study 36877502 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine invasive strategy
Number of subjects: 167
Study 36877543 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital psychological intervention (self-guided internet intervention for chronic pain)
Number of subjects: 85
Study 36877563 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified rehabilitation equipment 3 times a week
Number of subjects: 57
Study 36877563 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 57
Study 36877575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic involvement at diagnosis
Number of subjects: 20
Study 36877575 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated bilateral proptosis
Number of subjects: 20
Study 36877575 — intervention group
Group type: EXPERIMENTAL
Intervention: Diplopia
Number of subjects: 20
Study 36877575 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ophthalmic abnormalities
Number of subjects: 20
Study 36877575 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trends in pediatric cases
Number of subjects: 20
Study 36877666 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-layered cloth facemask
Number of subjects: 9
Study 36877726 — intervention group
Group type: EXPERIMENTAL
Intervention: Long health itinerary (admitted >3 days after fever onset)
Number of subjects: 784
Study 36877726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodstream infection (specifically non-typhoidal Salmonella)
Number of subjects: 784
Study 36877726 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaying factors (consulting traditional, private and/or multiple providers, rural residence, prehospital intravenous therapy, and prehospital overnight stays)
Number of subjects: 784
Study 36877726 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antibiotics reserved for hospital use, intravenous therapy, and prehospital overnight stays
Number of subjects: 784
Study 36877800 — intervention group
Group type: EXPERIMENTAL
Intervention: Grief COVID web-based intervention
Number of subjects: 114
Study 36877800 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 114
Study 36877807 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy (LDL-C target between 50 and 70 mg/dL)
Number of subjects: 4400
Study 36877807 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin treatment (rosuvastatin 20 mg or atorvastatin 40 mg)
Number of subjects: 4400
Study 36877807 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy
Number of subjects: 4400
Study 36877964 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-scope clips (OTSCs)
Number of subjects: 190
Study 36877964 — intervention group
Group type: COMPARATOR
Intervention: Standard hemostatic treatment
Number of subjects: 190
Study 36878187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 20
Study 36878187 — intervention group
Group type: COMPARATOR
Intervention: Sham IPC
Number of subjects: 20
Study 36878213 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine
Number of subjects: 20067
Study 36878213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20067
Study 36878216 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF+KI
Number of subjects: 49
Study 36878216 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF
Number of subjects: 49
Study 36878216 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC
Number of subjects: 49